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Variousenvironmentalandgeneticfactorsaﬀectthedevelopmentandprogressionofskincancersincludingmelanoma.Melanoma
developmentisinitiallytriggeredbyenvironmentalfactorsincluding ultraviolet(UV)light,andthengenetic/epigeneticalterations
occur in skin melanocytes. These ﬁrst triggers alter the conditions of numerous genes and proteins, and they induce and/or reduce
gene expression and activate and/or repress protein stability and activity, resulting in melanoma progression. Microphthalmia-
associated transcription factor (MITF)i sam a s t e rr e g u l a t o rg e n eo fm e l a n o c y t ed e v e l o p m e n ta n dd i ﬀerentiation and is also
associated with melanoma development and progression. To ﬁnd better approaches to molecular-based therapies for patients,
understanding MITF function in skin melanoma development and progression is important. Here, we review the molecular
networks associated with MITF in skin melanoma development and progression.
1.Introduction
Much evidence that environmental factors are correlated
with various diseases has been accumulating. The envi-
ronmental factors can be classiﬁed into physical [1–4],
chemical [5–8], and biological [9, 10] factors. In addition
to the environmental factors, genetic factors also have a
great inﬂuence on the development and pathogenesis of
various diseases [2, 11, 12]. Skin is a representative organ
that directly suﬀers from environmental factors. There is
much evidence showing that sunlight and ultraviolet light
induce various skin cancers with modulation of the signaling
of cell proliferation and DNA damage [13–16]. Therefore,
roles of skin cancer-related molecules should be discussed
with consideration of the eﬀects of environmental factors.
Moreover, the incidence of skin melanoma has recently been
increasing at a greater rate than that of any other cancer [17].
In the USA, 68,130 cases of invasive melanoma and at least
48,000 cases of melanoma in-situ were diagnosed in a year
[18]. Since melanoma is the most aggressive skin cancers
[17, 18], we focus on skin melanoma in this paper.
Not only studies on humans including epidemiological
research but also animal models can be useful for analyzing
melanomagenesis [19–23]. For example, exposure of skin to
oxygen might regulate development of benign melanocytic
tumors with modulation of tumor immunity in animal
models [19]. Ultraviolet (UV) light is correlated with
malignant transformation from benign melanocytic tumors
and melanoma [15, 24]. In addition to these environmental
factors,variouskindsofgeneticfactorshavebeenreportedas2 Journal of Skin Cancer
crucial factors of melanoma. For example, tyrosine kinases
are important for the development and pathogenesis of
melanoma in mice and humans [19, 21–23, 25–27]. Various
membrane traﬃcking-associated molecules have also been
reported to be involved in melanoma pathogenesis [28–
30]. Moreover, some acidic glycosphingolipids have been
reported to be expressed at high levels in melanomas and
promote their malignant properties by activating cell growth
and adhesion signals in melanoma cells [31–33].
Microphthalmia-associated transcription factor (MITF)
is believed to be one of the master molecules to regulate
melanomagenesis among the many previously reported
melanoma-associated molecules. Therefore, we selected
MITF as a cancer-associated molecule in melanoma and
introduce recent ﬁndings regarding MITF in this paper.
2. Results
Melanocytes, melanin-producing cells that are widely dis-
tributed in several tissues from fungi to primates on the long
evolutionary process, have multifunctionality for survival
strategy [34–41]. Melanocytes are also present in skin
surfaces and protect them from UV that damages DNA,
therebycausinggenotoxicmutationsorskincancers[42,43],
but once they transform, they can result in the development
of one of the most serious cancers, melanoma.
2.1. Microphthalmia-Associated Transcription Factor. The
MITF gene, encoding a basic-helix-loop-helix-leucine zipper
transcription factor, is expressed in melanocytes, retinal
pigmentedepithelium,mastcells,osteoclasts,andmelanoma
[36, 37, 40–42, 44–49]. MITF protein forms dimers and
binds to speciﬁc consensus DNA sequences in the promoter
regions of various target genes to regulate several events
including diﬀerentiation, proliferation, migration, invasion,
and tumorigenesis (Figure 1)[ 50].
2.2.RegulationofMITFExpressionandActivity. Severaltran-
scription factors directly control MITF gene transcription
to regulate melanocyte and melanoma development. Paired
box 3 (PAX3) and Sry-related HMG box 10 (SOX10), highly
correlatedwithmelanocytedevelopmentandmelanomagen-
esis [51–53], positively regulate MITF expression by directly
binding to MITF promoter regions [54–57]. Activation of
melanocortin 1 receptor (MC1R) by binding of alpha-
melanocyte stimulating hormone (α-MSH) induces cAMP
production via activation of adenylyl cyclase and phospho-
rylates cAMP response element-binding protein (CREB).
Phosphorylated CREB directly binds to the MITF promoter
regionandstimulatesMITF transcription[58,59].Wingless-
type(WNT)signalingisoftenactivatedinhumanmelanoma
[60–63]. Activation of Frizzled receptors by binding of
WNT molecules enhances interaction of β-catenin with
TCF/LEF transcription factors, resulting in stimulation of
MITF promoter activity [64–66].
Furthermore,MITFproteinismodiﬁedbyseveralfactors
after translation. Phosphorylation at Ser 301 of MITF is
induced by UV through p38 stress-activated kinase [67], and
Ser 298 of the protein is phosphorylated by GSK3β [65],
resulting in stimulation of MITFtranscriptional activity. The
c-KIT receptor activated by stem cell factor (SCF, c-KIT
ligand) phosphorylates Ser 73 and thereby increases MITF
transcriptional activity followed by immediate degradation
of MITF [59, 68], whereas sumoylation at Lys 182 and Lys
316 increases MITF transcriptional activity [69, 70].
2.3. Transcriptional Targets of MITF. MITF is associated
with cellular senescence, apoptosis, proliferation, migra-
tion/invasion, and diﬀerentiation through regulating tran-
scription of target genes.
Overcoming cellular senescence, acquisition of anti-
apoptotic activity, and promotion of proliferation are critical
cellulareventsfortheinitiationoftumorigenesis[50,71–75].
CDKN2A and WAF1 genes encode senescence mediator pro-
teins, p16INK4A and p14ARF,a n dp21Cip1,r e s p e c t i v e l y ,a n da r e
the well-known familial melanoma locus [71, 73, 76]. Copy
number of CyclinD1 (CCND1) gene, a cell cycle mediator, is
ampliﬁed in 25% of human melanomas [77]. MITF directly
binds to the promoter regions of p16Ink4a, p21Cip1,a n d
CyclinD1andpositivelyregulatestheirtranscription[78–80].
T-Box transcription factor 2 (TBX2) is highly expressed in
melanoma cell lines and represses p19ARF and p21Cip1,b o t h
of which are implicated as eﬀectors of senescence, promotes
proliferation, and suppresses senescence in melanoma [81,
82]. TBX2 has also been described as one of the MITF
target genes [81]. These reports indicate that MITF is linked
to melanoma development as a transcriptional activator of
senescence-/proliferation-associated genes.
Antiapoptotic eﬀect is a key process for melanoma
development. B-cell leukemia/lymphoma 2 (BCL2) is an anti-
apoptotic geneandiswidelyexpressedinhumanmelanomas
[83–85]. BCL2 is an MITF target gene and is activated
at the transcription level [86]. Baculoviral IAP repeat
containing 7/melanoma inhibitor of apoptosis (BIRC7/ML-
IAP), which is an antiapoptotic regulator, is highly expressed
in human melanomas [87] and provides resistance to
apoptosis-based chemotherapeutic treatments [88]. BIRC7
transcription is also directly activated by MITF, and over-
expression of BIRC7 rescued melanoma from apoptosis in
MITF-depleted melanoma cells [87]. Antioxidative stress
activity is important for melanocyte survival and melanoma
development. Oxidative stress from environmental factors
such as solar UV causes DNA damage and apoptosis.
Recently, apurinic/apyrimidinic endonuclease1/redox factor-1
(APEX1/Ref1) has been identiﬁed as a MITF target gene and
has been shown to be partially rescued from oxidative stress-
induced apoptosis in MITF-depleted cells [89]. Hypoxia-
inducible factor 1 α (HIF1α) has also been demonstrated to
be activated at the transcription level by direct MITF binding
to the HIF1α promoter region and acts as an antiapoptotic
factor in melanoma cells [90]. Antiapoptotic activity and
resistance to chemotherapy of melanoma are under the
control of MITF activity.
Angiogenesis and invasion are critical steps for tumor
progression, and these activities are enhanced in melanoma.
MITF depletion in melanoma cells represses not only
transcription of HIF1α but also that of vascular endothe-
lial growth factor (VEGF), which is a target of HIF1αJournal of Skin Cancer 3
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Figure 1: MITF-centered schematic scheme of cellular signaling on melanoma development and progression. Open arrows indicate direct
transcriptional targets of MITF. The amount of transcripts of these targets is regulated by direct MITF binding to cis-elements in their
promoter sequence. Black arrows or lines indicate signal cascades associated with melanoma development and progression. Arrows or lines
toward MITF mean direct association by binding to the MITF promoter region or MITF protein. αMSH: melanocyte-stimulating hormone;
BCL2: B-cell leukemia/lymphoma 2; BRN2: brain-2; CDK2/CDK4: cyclin-dependent kinase 2/4; CREB: cAMP-responsive element-binding
protein; DCT: dopachrome tautomerase; DIA1: diaphanous homolog 1; FZD: frizzled; GSK3β: glycogen synthase kinase 3 beta; HGF:
hepatocyte growth factor; HIF1α: hypoxia inducible factor 1, alpha subunit; MC1R: melanocortin 1 receptor; MDM2: transformed mouse
3T3 cell double minute 2; PMEL17: premelanosome protein; RB1: retinoblastoma 1; SCF: stem cell factor; SNAI2: snail homolog 2; SOX10:
Sry-related HMG box 10; TYR: tyrosinase, WNT: wingless-related MMTV integration site.
and has been demonstrated to be a major contributor
to angiogenesis [90]. The c-MET protooncogene, which
enc odeshepat ocyt egr o wthfact orr ec ept or(HGFR),ishighly
expressed in human melanomas and linked to metastatic
potential in melanomas. c-MET transcription is directly
regulated by MITF [91]. SNAI2 has been reported to be
a key player for epithelial-mesenchymal transition (EMT),
which is a crucial phenomenon during invasion, metas-
tasis of melanoma, by repressing E-cadherin transcription
and stimulating ﬁbronectin expression, and MITF directly
activates the transcription level of SNAI2 [92–94]. On the
other hand, MITF directly binds to the promoter region of
diaphanous homolog 1 (DIAPH1, DIA1) gene and activates
its transcription, resulting in inhibiting the invasiveness of
melanoma by activation of actin polymerization [95].
MITF is also well known as a master regulator of melanin
production. Melanin pigment is synthesized from tyrosine
via an enzymatic process. This process is catalyzed by tyrosi-
nase family proteins, tyrosinase (TYR), tyrosinase-related
protein 1 (TYRP1), and DCT (dopachrome tautomerase).
After melanin production, melanin pigment is stored in
melanosomes, which are organelles containing melanin,
and is transported to the skin for UV protection. MART1
and PMEL17 are localized in melanosomes and contribute
to melanosome maturation [96–99]. Direct regulation of
melanin synthesis-associated genes at transcription levels by
MITF stimulates melanin production. [100–103].
2.4. “Two-Faced” Function of Mitf in Melanoma Develop-
ment and Progression. MITF is expressed in most human
melanomas, and stability of its expression is essential for
melanoma cell proliferation and survival [104]. In addition,
ampliﬁcation of the MITF locus was observed in human
metastatic melanomas [105]. However, the expression level
of MITF in melanomas is signiﬁcantly lower than that in
normal melanocytes, and higher expression level of MITF in
melanoma represses cell proliferation even in the presence
of oncogenic BRAF [106]. Most likely, MITF plays both
cancer-promoting and cancer-inhibiting roles alternated by4 Journal of Skin Cancer
the expression level and/or activity. A low level of MITF
expression promotes proliferation in melanoma, whereas
a high level of MITF expression promotes diﬀerentiation
through induction of cellular senescence and melanin pro-
duction [107–109]. MITF has the ability to upregulate
transcription of melanoma-promoting genes (e.g., CyclinD1,
BCL2, c-MET) and also that of melanoma-repressing genes
(e.g., p16Ink4a, p21Cip1, DIAHP1). Taken together, MITF
has two-faced functions in melanoma development and
progression, and strict regulation of MITF in its expression
and/or activity is likely to switch melanocytes to melanoma
cells.
3. Concluding Remarks
Skin melanoma is an aggressive tumor of the skin, and
patients have a poor prognosis. Analysis of the expression
proﬁle and function of MITF and identiﬁcation of its target
genesareimportanttobetterunderstandthecomplexsystem
of melanoma development and progression. Expression pat-
terns, functions, and many target genes of MITF have been
reported by a number of groups, though the complicated
functions of MITF in skin melanoma development and
progression are still not well understood. Extensive analyses
of MITF will lead to a better understanding of melanoma
development and progression and to the establishment of
more eﬀective therapeutics.
References
[1] M. Ida-Eto, N. Ohgami, M. Iida et al., “Partial requirement
of endothelin receptor B in spiral ganglion neurons for
postnatal development of hearing,” Journal of Biological
Chemistry, vol. 286, no. 34, pp. 29621–29626, 2011.
[2] N. Ohgami, M. Ida-Eto, N. Sakashita et al., “Partial impair-
mentofc-Retattyrosine1062accelerates age-related hearing
loss in mice,” Neurobiology of Aging. In press.
[3] P. Wefstaedt, V. Scheper, H. Rieger, T. Lenarz, and T.
St¨ over, “Neurotrophic factors of the GDNF family and their
receptors are detectable in spiral ganglion cells of normal
hearingaswellasofdeafenedrats,”Laryngo-Rhino-Otologie,
vol. 85, no. 11, pp. 802–808, 2006.
[4] J. Ylikoski, U. Pirvola, M. Moshnyakov, J. Palgi, U. Arumae,
and M. Saarma, “Expression patterns of neurotrophin and
their receptor mRNAs in the rat inner ear,” Hearing Research,
vol. 65, no. 1-2, pp. 69–78, 1993.
[5] K. Hossain, A. A. Akhand, M. Kato et al., “Arsenite induces
apoptosis of murine T lymphocytes through membrane
raft-linked signaling for activation of c-Jun amino-terminal
kinase,” Journal of Immunology, vol. 165, no. 8, pp. 4290–
4297, 2000.
[6] M. Kato, M. Y. Kumasaka, K. Takeda et al., “L-cysteine as a
regulator for arsenic-mediated cancer-promoting and anti-
cancereﬀects,”ToxicologyinVitro,vol.25,no.3,pp.623–629,
2011.
[7] M. Kato, S. Onuma, Y. Kato et al., “Toxic elements in
well water from Malaysia,” Toxicological and Environmental
Chemistry, vol. 92, no. 9, pp. 1609–1612, 2010.
[8] M. Kato, K. Takeda, K. Hossain et al., “A redox-linked
novel pathway for arsenic-mediated RET tyrosine kinase
activation,” Journal of Cellular Biochemistry, vol. 110, no. 2,
pp. 399–407, 2010.
[9] M. Kato, T. Hattori, R. Ikeda et al., “Amount of pollen has an
eﬀect on the systemic and local levels of soluble ICAM-1 in
patients with seasonal allergic rhinitis,” Allergy, vol. 51, no. 2,
pp. 128–132, 1996.
[ 1 0 ]M .K a t o ,T .H a t t o r i ,Y .K a t o ,Y .M a t s u m o t o ,T .Y a m a s h i t a ,
and I. Nakashima, “Elevated soluble tumor necrosis factor
receptor levels in seasonal allergic rhinitis patients,” Allergy,
vol. 54, no. 3, pp. 278–282, 1999.
[11] M. Kato, K. Takeda, Y. Kawamoto et al., “Repair by Src
kinase of function-impaired RET with multiple endocrine
neoplasia type 2A mutation with substitutions of tyrosines
in the COOH-terminal kinase domain for phenylalanine,”
Cancer Research, vol. 62, no. 8, pp. 2414–2422, 2002.
[12] N. Ohgami, M. Ida-Eto, T. Shimotake et al., “c-Ret-mediated
hearing loss in mice with Hirschsprung disease,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 107, no. 29, pp. 13051–13056, 2010.
[13] M. Kato, M. Iida, Y. Goto, T. Kondo, and I. Yajima, “Sunlight
exposure-mediated DNA damage in young adults,” Cancer
Epidemiology Biomarkers and Prevention, vol. 20, no. 8, pp.
1622–1628, 2011.
[14] M. Kato, T. Iwashita, A. A. Akhand et al., “Molecular
mechanism of activation and superactivation of Ret tyrosine
kinases by ultraviolet light irradiation,” Antioxidants and
Redox Signaling, vol. 2, no. 4, pp. 841–849, 2000.
[15] M. Kato, T. Iwashita, K. Takeda et al., “Ultraviolet light
induces redox reaction-mediated dimerization and superac-
tivation of oncogenic Ret tyrosine kinases,” Molecular Biology
of the Cell, vol. 11, no. 1, pp. 93–101, 2000.
[16] M. Kato, N. Ohgami, Y. Kawamoto et al., “Protective eﬀect
of hyperpigmented skin on UV-mediated cutaneous cancer
development,” Journal of Investigative Dermatology, vol. 127,
no. 5, pp. 1244–1249, 2007.
[17] M. R. Hussein, A. K. Haemel, O. Sodilovsky, and G. S. Wood,
“Genomic instability in radial growth phase melanoma
cell lines after ultraviolet irradiation,” Journal of Clinical
Pathology, vol. 58, no. 4, pp. 389–396, 2005.
[18] D. S. Rigel, “Epidemiology of melanoma,” Seminars in
Cutaneous Medicine and Surgery, vol. 29, no. 4, pp. 204–209,
2010.
[19] M. Kato, W. Liu, A. A. Akhand et al., “Linkage between
melanocytic tumor development and early burst of Ret pro-
tein expression for tolerance induction in metallothionein-
I/ret transgenic mouse lines,” Oncogene,v o l .1 8 ,n o .3 ,p p .
837–842, 1999.
[20] M.Kato,W.Liu,H.Yietal.,“TheherbalmedicineSho-saiko-
to inhibits growth and metastasis of malignant melanoma
primarily developed in ret-transgenic mice,” Journal of
Investigative Dermatology, vol. 111, no. 4, pp. 640–644, 1998.
[21] M. Kato, K. Takeda, Y. Kawamoto et al., “RET tyrosine
kinase enhances hair growth in association with promotion
of melanogenesis,” Oncogene, vol. 20, no. 51, pp. 7536–7541,
2001.
[22] M. Kato, K. Takeda, Y. Kawamoto et al., “c-kit-targeting
immunotherapy for hereditary melanoma in a mouse
model,” Cancer Research, vol. 64, no. 3, pp. 801–806, 2004.
[23] M. Y. Kumasaka, I. Yajima, K. Hossain et al., “A novel mouse
model for de novo melanoma,” Cancer Research, vol. 70, no.
1, pp. 24–29, 2010.
[24] M. Kato, W. Liu, A. A. Akhand et al., “Ultraviolet radiation
induces both full activation of Ret kinase and malig-
nant melanocytic tumor promotion in RFP-RET-transgenicJournal of Skin Cancer 5
mice,” J o u r n a lo fI n v e s t i g a t i v eD e r m a t o l o g y , vol. 115, no. 6,
pp. 1157–1158, 2000.
[25] T. Iwamoto, M. Takahashi, M. Ito et al., “Aberrant melano-
genesis and melanocytic tumour development in transgenic
mice that carry a metallothionein/ret fusion gene,” EMBO
Journal, vol. 10, no. 11, pp. 3167–3175, 1991.
[26] M. Kato, M. Takahashi, A. A. Akhand et al., “Transgenic
mouse model for skin malignant melanoma,” Oncogene, vol.
17, no. 14, pp. 1885–1888, 1998.
[27] Y. Ohshima, I. Yajima, K. Takeda et al., “c-RET molecule in
malignant melanoma from oncogenic RET-carrying trans-
genic mice and human cell lines,” PLoS ONE,v o l .5 ,n o .4 ,
Article ID e10279, 2010.
[28] M. Kato and W. Wickner, “Ergosterol is required for the
Sec18/ATP-dependent priming step of homotypic vacuole
fusion,” EMBO Journal, vol. 20, no. 15, pp. 4035–4040, 2001.
[29] M. Kato and W. Wickner, “Vam10p deﬁnes a Sec18p-
independent step of priming that allows yeast vacuole
tethering,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 100, no. 11, pp. 6398–6403,
2003.
[30] A. Richmond, H. F. Guo, P. Dhawan, and J. Yang, “How do
chemokine/chemokine receptor activations aﬀect tumorige-
nesis?” Novartis Foundation Symposium, vol. 256, pp. 74–89,
2004.
[31] K. Hamamura, K. Furukawa, T. Hayashi et al., “Ganglioside
GD3 promotes cell growth and invasion through p130Cas
and paxillin in malignant melanoma cells,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 102, no. 31, pp. 11041–11046, 2005.
[32] Y. Ohkawa, S. Miyazaki, K. Hamamura et al., “Ganglioside
GD3 enhances adhesion signals and augments malignant
properties of melanoma cells by recruiting integrins to
glycolipid-enriched microdomains,” Journal of Biological
Chemistry, vol. 285, no. 35, pp. 27213–27223, 2010.
[33] Y. Yamauchi, K. Furukawa, K. Hamamura, and K. Furukawa,
“Positive feedback loop between PI3K-Akt-mTORC1 sig-
naling and the lipogenic pathway boosts Akt signaling:
induction of the lipogenic pathway by a melanoma antigen,”
Cancer Research, vol. 71, no. 14, pp. 4989–4997, 2011.
[34] M. S. Blois, “Vitamin D, sunlight, and natural selection,”
Science, vol. 159, no. 815, p. 652, 1968.
[35] S. Kamei, I. Yajima, H. Yamamoto et al., “Characterization
of a novel member of the FGFR family, HrFGFR, in
Halocynthia roretzi,” Biochemical and Biophysical Research
Communications, vol. 275, no. 2, pp. 503–508, 2000.
[36] M. Kumasaka, S. Sato, I. Yajima, C. R. Goding, and H.
Yamamoto, “Regulation of melanoblast and retinal pigment
epithelium development by Xenopus laevis Mitf,” Develop-
mental Dynamics, vol. 234, no. 3, pp. 523–534, 2005.
[37] M. Kumasaka, S. Sato, I. Yajima, and H. Yamamoto, “Isola-
tionanddevelopmentalexpressionoftyrosinasefamilygenes
in Xenopus laevis,” Pigment Cell Research,v o l .1 6 ,n o .5 ,p p .
455–462, 2003.
[38] I. Puig, I. Yajima, J. Bonaventure, V. Delmas, and L. Larue,
“The tyrosinase promoter is active in a subset of vagal neural
crest cells during early development in mice,” Pigment Cell
and Melanoma Research, vol. 22, no. 3, pp. 331–334, 2009.
[39] S. Sato, R. Toyoda, Y. Katsuyama et al., “Structure and
developmental expression of the ascidian TRP gene: insights
into the evolution of pigment cell-speciﬁc gene expression,”
Developmental Dynamics, vol. 215, no. 3, pp. 225–237, 1999.
[40] I. Yajima, K. Endo, S. Sato et al., “Cloning and functional
analysis of ascidian Mitf in vivo: insights into the origin of
vertebrate pigment cells,” Mechanisms of Development, vol.
120, no. 12, pp. 1489–1504, 2003.
[41] I. Yajima and L. Larue, “The location of heart melanocytes
is speciﬁed and the level of pigmentation in the heart
may correlate with coat color,” Pigment Cell and Melanoma
Research, vol. 21, no. 4, pp. 471–476, 2008.
[42] C. R. Goding, “Melanocytes: the new black,” International
Journal of Biochemistry and Cell Biology,v o l .3 9 ,n o .2 ,p p .
275–279, 2007.
[43] A. Robins, Biological Perspectives on Human Pigmentation,
Cambridge University Press, New York, NY, USA, 1991.
[44] T. J. Hemesath, E. Steingrimsson, G. McGill et al., “Microph-
thalmia, a critical factor in melanocyte development, deﬁnes
a discrete transcription factor family,” Genes and Develop-
ment, vol. 8, no. 22, pp. 2770–2780, 1994.
[ 4 5 ]C .A .H o d g k i n s o n ,K .J .M o o r e ,A .N a k a y a m ae ta l . ,“ M u t a -
tions at the mouse Microphthalmia locus are associated with
defects in a gene encoding a novel basic-helix-loop-helix-
zipper protein,” Cell, vol. 74, no. 2, pp. 395–404, 1993.
[46] E. Steingr´ ımsson, N. G. Copeland, and N. A. Jenkins,
“Melanocytes and the Microphthalmia transcription factor
network,” Annual Review of Genetics, vol. 38, pp. 365–411,
2004.
[47] H. R. Widlund and D. E. Fisher, “Microphthalamia-
associatedtranscriptionfactor:acriticalregulatorofpigment
cell development and survival,” Oncogene, vol. 22, no. 20, pp.
3035–3041, 2003.
[48] I. Yajima, S. Sato, T. Kimura et al., “An L1 element intronic
insertion in the black-eyed white (Mitf(mi-bw)) gene: the
loss of a single Mitf isoform responsible for the pigmentary
defect and inner ear deafness,” Human Molecular Genetics,
vol. 8, no. 8, pp. 1431–1441, 1999.
[49] K.I.Yasumoto,S.Amae,T.Udono,N.Fuse,K.Takeda,andS.
Shibahara, “A big gene linked to small eyes encodes multiple
Mitf isoforms: many promoters make light work,” Pigment
Cell Research, vol. 11, no. 6, pp. 329–336, 1998.
[50] Y. Cheli, M. Ohanna, R. Ballotti, and C. Bertolotto, “Fifteen-
year quest for Microphthalmia-associated transcription fac-
tor target genes,” Pigment Cell and Melanoma Research, vol.
23, no. 1, pp. 27–40, 2010.
[51] H. T. Khong and S. A. Rosenberg, “The Waardenburg
syndrome type 4 gene, SOX10, is a novel tumor-associated
antigen identiﬁed in a patient with a dramatic response to
immunotherapy,” Cancer Research, vol. 62, no. 11, pp. 3020–
3023, 2002.
[52] J. B. Mascarenhas, E. L. Littlejohn, R. J. Wolsky et al., “PAX3
and SOX10 activate MET receptor expression in melanoma,”
Pigment Cell and Melanoma Research, vol. 23, no. 2, pp. 225–
237, 2010.
[53] R.S.Plummer,C.R.Shea,M.Nelsonetal.,“PAX3expression
in primary melanomas and nevi,” Modern Pathology, vol. 21,
no. 5, pp. 525–530, 2008.
[54] N. Bondurand, V. Pingault, D. E. Goerich et al., “Interaction
among SOX10, PAX3 and MITF, three genes altered in
Waardenburg syndrome,” Human Molecular Genetics, vol. 9,
no. 13, pp. 1907–1917, 2000.
[55] M. Lee, J. Goodall, C. Verastegui, R. Ballotti, and C. R.
Goding, “Direct regulation of the Microphthalmia pro-
moter by Sox10 links Waardenburg-Shah syndrome (WS4)-
associated hypopigmentation and deafness to WS2,” Journal
of Biological Chemistry, vol. 275, no. 48, pp. 37978–37983,
2000.
[56] S. B. Potterf, M. Furumura, K. J. Dunn, H. Arnheiter, and
W. J. Pavan, “Transcription factor hierarchy in Waardenburg6 Journal of Skin Cancer
syndrome: regulation of MITF expression by SOX10 and
PAX3,” Human Genetics, vol. 107, no. 1, pp. 1–6, 2000.
[57] C. Verastegui, K. Bille, J. P. Ortonne, and R. Ballotti,
“Regulation of the Microphthalmia-associated transcription
factor gene by the Waardenburg syndrome type 4 gene,
SOX10,” Journal of Biological Chemistry, vol. 275, no. 40, pp.
30757–30760, 2000.
[58] C.Bertolotto,P.Abbe,T.J.Hemesathetal.,“Microphthalmia
gene product as a signal transducer in cAMP-induced
diﬀerentiation of melanocytes,” Journal of Cell Biology, vol.
142, no. 3, pp. 827–835, 1998.
[59] E.R.Price,H.F.Ding,T.Badalianetal.,“Lineage-speciﬁcsig-
naling in melanocytes. C-Kit stimulation recruits p300/CBP
to Microphthalmia,” Journal of Biological Chemistry, vol. 273,
no. 29, pp. 17983–17986, 1998.
[60] V. Delmas, F. Beermann, S. Martinozzi et al., “β-Catenin
induces immortalization of melanocytes by suppress-
ing p16INK4a expression and cooperates with N-Ras in
melanoma development,” Genes and Development, vol. 21,
no. 22, pp. 2923–2935, 2007.
[61] R.H.Giles,J.H.vanEs,andH.Clevers,“Caught upinaWnt
storm: Wnt signaling in cancer,” Biochimica et Biophysica
Acta, vol. 1653, no. 1, pp. 1–24, 2003.
[62] K.Omholt,A.Platz,U.Ringborg,andJ.Hansson,“Cytoplas-
mic and nuclear accumulation of β-catenin is rarely caused
by CTNNB1 exon 3 mutations in cutaneous malignant
melanoma,”InternationalJournalofCancer,v ol.92,no .6,pp .
839–842, 2001.
[63] D. L. Rimm, K. Caca, G. Hu, F. B. Harrison, and E. R.
Fearon, “Frequent nuclear/cytoplasmic localization of β-
catenin without exon 3 mutations in malignant melanoma,”
American Journal of Pathology, vol. 154, no. 2, pp. 325–329,
1999.
[64] R.I.Dorsky,D.W.Raible,andR.T.Moon,“Directregulation
ofnacre,azebraﬁshMITFhomologrequiredforpigmentcell
formation,bytheWntpathway,”GenesandDevelopment,vol.
14, no. 2, pp. 158–162, 2000.
[65] K. Takeda, C. Takemoto, I. Kobayashi et al., “Ser298 of
MITF, a mutation site in Waardenburg syndrome type 2, is
a phosphorylation site with functional signiﬁcance,” Human
Molecular Genetics, vol. 9, no. 1, pp. 125–132, 2000.
[66] H. R. Widlund, M. A. Horstmann, E. R. Price et al.,
“β-Catenin-induced melanoma growth requires the down-
stream target Microphthalmia-associated transcription fac-
tor,” J o u r n a lo fC e l lB i o l o g y , vol. 158, no. 6, pp. 1079–1087,
2002.
[67] K. C. Mansky, U. Sankar, J. Han, and M. C. Ostrowski,
“Microphthalmia transcription factor is a target of the p38
MAPK pathway in response to receptor activator of NF-κB
ligandsignaling,”JournalofBiologicalChemistry,vol.277,no.
13, pp. 11077–11083, 2002.
[ 6 8 ]M .W u ,T .J .H e m e s a t h ,C .M .T a k e m o t oe ta l . ,“ c - K i t
triggers dual phosphorylations, which couple activation and
degradationoftheessentialmelanocytefactorMi,”Genesand
Development, vol. 14, no. 3, pp. 301–312, 2000.
[ 6 9 ]A .J .M i l l e r ,C .L e v y ,I .J .D a v i s ,E .R a z i n ,a n dD .E .F i s h e r ,
“Sumoylation of MITF and its related family members TFE3
and TFEB,” Journal of Biological Chemistry, vol. 280, no. 1,
pp. 146–155, 2005.
[70] H. Murakami and H. Arnheiter, “Sumoylation modulates
transcriptional activity of MITF in a promoter-speciﬁc
manner,” Pigment Cell Research, vol. 18, no. 4, pp. 265–277,
2005.
[71] D. C. Bennett, “How to make a melanoma: what do we know
of the primary clonal events?” Pigment Cell and Melanoma
Research, vol. 21, no. 1, pp. 27–38, 2008.
[72] M. Collado, J. Gil, A. Efeyan et al., “Tumour biology:
senescence in premalignant tumours,” Nature, vol. 436, no.
7051, p. 642, 2005.
[73] V. C. Gray-Schopfer, S. C. Cheong, H. Chong et al., “Cellular
senescence in naevi and immortalisation in melanoma: a role
forp16?”BritishJournalofCancer,vol.95,no.4,pp.496–505,
2006.
[ 7 4 ]C .M i c h a l o g l o u ,L .C .W .V r e d e v e l d ,M .S .S o e n g a se ta l . ,
“BRAFE600-associated senescence-like cell cycle arrest of
human naevi,” Nature, vol. 436, no. 7051, pp. 720–724, 2005.
[75] W. J. Mooi and D. S. Peeper, “Oncogene-induced cell
senescence—haltingontheroadtocancer,”TheNewEngland
Journal of Medicine, vol. 355, no. 10, pp. 1037–1046, 2006.
[76] M. J. Vidal, F. Loganzo Jr., A. R. de Oliveira, N. K. Hayward,
and A. P. Albino, “Mutations and defective expression
of the WAF1 p21 tumour-suppressor gene in malignant
melanomas,” Melanoma Research, vol. 5, no. 4, pp. 243–250,
1995.
[ 7 7 ]E .R .S a u t e r ,U .C .Y e o ,A .v o nS t e m me ta l . ,“ C y c l i nD 1
is a candidate oncogene in cutaneous melanoma,” Cancer
Research, vol. 62, no. 11, pp. 3200–3206, 2002.
[78] S. Carreira, J. Goodall, I. Aksan et al., “Mitf cooperates with
Rb1 and activates p21Cip1 expression to regulate cell cycle
progression,” Nature, vol. 433, no. 7027, pp. 764–769, 2005.
[79] J. Du, H. R. Widlund, M. A. Horstmann et al., “Critical role
of CDK2 for melanoma growth linked to its melanocyte-
speciﬁc transcriptional regulation by MITF,” Cancer Cell, vol.
6, no. 6, pp. 565–576, 2004.
[80] A. E. Loercher, E. M. H. Tank, R. B. Delston, and J. W.
Harbour, “MITF links diﬀerentiation with cell cycle arrest in
melanocytes by transcriptional activation of INK4A,” Journal
of Cell Biology, vol. 168, no. 1, pp. 35–40, 2005.
[81] S. Carreira, B. Liu, and C. R. Goding, “The gene encoding
the T-box factor Tbx2 is a target for the Microphthalmia-
associated transcription factor in melanocytes,” Journal of
BiologicalChemistry,vol.275,no.29,pp.21920–21927,2000.
[82] K.W.Vance,S.Carreira,G.Brosch,andC.M.Goding,“Tbx2
is overexpressed and plays an important role in maintaining
proliferation and suppression of senescence in melanomas,”
Cancer Research, vol. 65, no. 6, pp. 2260–2268, 2005.
[83] L.Cerroni,H.P.Soyer,andH.Kerl,“bcl-2proteinexpression
in cutaneous malignant melanoma and benign melanocytic
nevi,” American Journal of Dermatopathology, vol. 17, no. 1,
pp. 7–11, 1995.
[84] J. A. Ramsay, L. From, and H. J. Kahn, “bcl-2 protein
expression in melanocytic neoplasms of the skin,” Modern
Pathology, vol. 8, no. 2, pp. 150–154, 1995.
[85] E.Selzer,H.Schlagbauer-Wadl,I.Okamoto,H.Pehamberger,
R. P¨ otter, and B. Jansen, “Expression of Bcl-2 family mem-
bers in human melanocytes, in melanoma metastases and in
melanoma cell lines,” Melanoma Research,v o l .8 ,n o .3 ,p p .
197–203, 1998.
[86] G.G.McGill,M.Horstmann,H.R.Widlundetal.,“Bcl2reg-
ulation by the melanocyte master regulator Mitf modulates
lineage survival and melanoma cell viability,” Cell, vol. 109,
no. 6, pp. 707–718, 2002.
[87] D. Vucic, H. R. Stennicke, M. T. Pisabarro, G. S. Salvesen,
and V. M. Dixit, “ML-IAP, a novel inhibitor of apoptosis that
is preferentially expressed in human melanomas,” Current
Biology, vol. 10, no. 21, pp. 1359–1366, 2000.Journal of Skin Cancer 7
[88] H. Chang and A. D. Schimmer, “Livin/melanoma inhibitor
of apoptosis protein as a potential therapeutic target for
thetreatmentofmalignancy,”MolecularCancerTherapeutics,
vol. 6, no. 1, pp. 24–30, 2007.
[89] F. Liu, Y. Fu, and F. L. Meyskens, “MiTF regulates cellular
response to reactive oxygen species through transcriptional
regulation of APE-1/Ref-1,” Journal of Investigative Derma-
tology, vol. 129, no. 2, pp. 422–431, 2009.
[90] R. Busc` a, E. Berra, C. Gaggioli et al., “Hypoxia-inducible
factor 1α is a new target of Microphthalmia- associated
transcription factor (MITF) in melanoma cells,” Journal of
Cell Biology, vol. 170, no. 1, pp. 49–59, 2005.
[91] G. G. McGill, R. Haq, E. K. Nishimura, and D. E. Fisher,
“c-Met expression is regulated by Mitf in the melanocyte
lineage,” Journal of Biological Chemistry, vol. 281, no. 15, pp.
10365–10373, 2006.
[92] S. A. Mani, W. Guo, M. J. Liao et al., “The epithelial-
mesenchymal transition generates cells with properties of
stem cells,” Cell, vol. 133, no. 4, pp. 704–715, 2008.
[93] M. A. Nieto, “The snail superfamily of zinc-ﬁnger transcrip-
tion factors,” Nature Reviews Molecular Cell Biology, vol. 3,
no. 3, pp. 155–166, 2002.
[94] M.S´ anchez-Mart´ ın,A.Rodr´ ıguez-Garc´ ıa,J.P´ erez-Losada,A.
Sagrera, A. P. Read, and I. S´ anchez-Garc´ ıa, “SLUG (SNA12)
deletions in patients with Waardenburg disease,” Human
Molecular Genetics, vol. 11, no. 25, pp. 3231–3236, 2002.
[95] S. Carreira, J. Goodall, L. Denat et al., “Mitf regulation
of Dia1 controls melanoma proliferation and invasiveness,”
Genes and Development, vol. 20, no. 24, pp. 3426–3439, 2006.
[96] J. F. Berson, D. C. Harper, D. Tenza, G. Raposo, and M.
S. Marks, “Pmel17 initiates premelanosome morphogenesis
within multivesicular bodies,” Molecular Biology of the Cell,
vol. 12, no. 11, pp. 3451–3464, 2001.
[97] T. Hoashi, H. Watabe, J. Muller, Y. Yamaguchi, W. D. Vieira,
and V. J. Hearing, “MART-1 is required for the function of
the melanosomal matrix protein PMEL17/GP100 and the
maturationofmelanosomes,”JournalofBiologicalChemistry,
vol. 280, no. 14, pp. 14006–14016, 2005.
[ 9 8 ]G .R a p o s o ,D .T e n z a ,D .M .M u r p h y ,J .F .B e r s o n ,a n dM .
S. Marks, “Distinct protein sorting and localization to pre-
melanosomes, melanosomes, and lysosomes in pigmented
melanocytic cells,” Journal of Cell Biology, vol. 152, no. 4, pp.
809–824, 2001.
[99] C. Wasmeier, A. N. Hume, G. Bolasco, and M. C. Seabra,
“Melanosomes at a glance,” Journal of Cell Science, vol. 121,
part 24, pp. 3995–3999, 2008.
[100] C. Bertolotto, R. Busc` a, P. Abbe et al., “Diﬀerent cis-acting
elements are involved in the regulation of TRP1 and TRP2
promoter activities by cyclic AMP: pivotal role of M boxes
(GTCATGTGCT) and of Microphthalmia,” Molecular and
Cellular Biology, vol. 18, no. 2, pp. 694–702, 1998.
[101] J. Du, A. J. Miller, H. R. Widlund, M. A. Horstmann,
S. Ramaswamy, and D. E. Fisher, “MLANA/MART1 and
SILV/PMEL17/GP100 are transcriptionally regulated by
MITF in melanocytes and melanoma,” American Journal of
Pathology, vol. 163, no. 1, pp. 333–343, 2003.
[102] K. I. Yasumoto, K. Yokoyama, K. Takahashi, Y. Tomita,
and S. Shibahara, “Functional analysis of Microphthalmia-
associated transcription factor in pigment cell-speciﬁc tran-
scription of the human tyrosinase family genes,” Journal of
Biological Chemistry, vol. 272, no. 1, pp. 503–509, 1997.
[103] U. Yavuzer, E. Keenan, P. Lowings, J. Vachtenheim, G. Currie,
and C. R. Goding, “The Microphthalmia gene product
interacts with the retinoblastoma protein in vitro and is a
target for deregulation of melanocyte-speciﬁc transcription,”
Oncogene, vol. 10, no. 1, pp. 123–134, 1995.
[104] C. Levy, M. Khaled, and D. E. Fisher, “MITF: master regu-
lator of melanocyte development and melanoma oncogene,”
Trends in Molecular Medicine, vol. 12, no. 9, pp. 406–414,
2006.
[105] L. A. Garraway, H. R. Widlund, M. A. Rubin et al., “Inte-
grative genomic analyses identify MITF as a lineage survival
oncogene ampliﬁed in malignant melanoma,” Nature, vol.
436, no. 7047, pp. 117–122, 2005.
[106] C. Wellbrock and R. Marais, “Elevated expression of MITF
counteracts B-RAF-stimulated melanocyte and melanoma
cell proliferation,” Journal of Cell Biology, vol. 170, no. 5, pp.
703–708, 2005.
[107] C. Goding and F. L. Meyskens Jr., “Microphthalmic-
associated transcription factor integrates melanocyte biology
and melanoma progression,” Clinical Cancer Research, vol.
12, no. 4, pp. 1069–1073, 2006.
[108] V. Gray-Schopfer, C. Wellbrock, and R. Marais, “Melanoma
biologyandnewtargetedtherapy,”Nature,vol.445,no.7130,
pp. 851–857, 2007.
[109] K. S. Hoek and C. R. Goding, “Cancer stem cells ver-
sus phenotype-switching in melanoma,” Pigment Cell and
Melanoma Research, vol. 23, no. 6, pp. 746–759, 2010.